Literature DB >> 2315605

Absence of correlations between indices of systemic inflammation and synovial fluid interleukin 1 (alpha and beta) in rheumatic diseases.

F S di Giovine1, S Poole, R D Situnayake, M Wadhwa, G W Duff.   

Abstract

There are two forms of the cytokine interleukin 1 (IL1), produced by two distinct genes encoding a neutral (IL1 beta) and an acidic (IL1 alpha) peptide. They have powerful pro-inflammatory, immunopotentiating, catabolic and arthritogenic properties in vivo and have been implicated in the pathogenesis of rheumatic diseases. In this study, using specific immunoassays, we have measured both IL1 alpha and IL1 beta levels in synovial fluids (SF) from a large number of patients with different rheumatic diseases. Biologically significant levels of both cytokines were found in SF from patients with different forms of arthritis, but no correlations were found with any of the measures of disease activity that we tested. We also describe the presence in joint exudates of biological inhibitor(s) that neutralize IL1-induced T-cell activation. This is the first report of IL1 alpha and IL1 beta measurements in the same synovial exudates and also of the comparison of local levels of these cytokines with conventional indices of systemic inflammation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2315605     DOI: 10.1007/bf00541321

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  33 in total

1.  Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc. Natl. Acad. Sci. USA 1984. 81: 7907-7911.

Authors:  Philip E Auron; Andrew C Webb; Lanny J Rosenwasser; Steven F Mucci; Alexander Rich; Sheldon M Wolff; Charles A Dinarello
Journal:  J Immunol       Date:  2007-05-01       Impact factor: 5.422

2.  Purification of granulocyte neutral protease from human blood and rheumatoid synovial fluid.

Authors:  R H Pryce-Jones; G C Wood
Journal:  Biochim Biophys Acta       Date:  1975-08-26

3.  Isolation of an interleukin-1-like factor from human joint effusions.

Authors:  D D Wood; E J Ihrie; C A Dinarello; P L Cohen
Journal:  Arthritis Rheum       Date:  1983-08

4.  Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1.

Authors:  F S Di Giovine; S E Malawista; G Nuki; G W Duff
Journal:  J Immunol       Date:  1987-05-15       Impact factor: 5.422

5.  Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs.

Authors:  C J March; B Mosley; A Larsen; D P Cerretti; G Braedt; V Price; S Gillis; C S Henney; S R Kronheim; K Grabstein
Journal:  Nature       Date:  1985 Jun 20-26       Impact factor: 49.962

Review 6.  Interleukin-1: amino acid sequences, multiple biological activities and comparison with tumor necrosis factor (cachectin).

Authors:  C A Dinarello
Journal:  Year Immunol       Date:  1986

Review 7.  Interleukin-1.

Authors:  C A Dinarello
Journal:  Rev Infect Dis       Date:  1984 Jan-Feb

8.  Identification of a specific interleukin 1 inhibitor in the urine of febrile patients.

Authors:  Z Liao; R S Grimshaw; D L Rosenstreich
Journal:  J Exp Med       Date:  1984-01-01       Impact factor: 14.307

9.  Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro.

Authors:  G J Darlington; D R Wilson; L B Lachman
Journal:  J Cell Biol       Date:  1986-09       Impact factor: 10.539

10.  Potentiation of the T-lymphocyte response to mitogens. I. The responding cell.

Authors:  I Gery; R K Gershon; B H Waksman
Journal:  J Exp Med       Date:  1972-07-01       Impact factor: 14.307

View more
  8 in total

1.  Interleukin 1 beta in synovial fluid is related to local disease activity in rheumatoid arthritis.

Authors:  M Rooney; J A Symons; G W Duff
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

2.  Serum levels of interleukin-1b, tumour necrosis factor-a and interleukin-2 in rheumatoid arthritis. Correlation with disease activity.

Authors:  L Altomonte; A Zoli; L Mirone; P Scolieri; M Magaró
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

3.  Interleukin-8 (IL-8) in synovial fluid of rheumatoid and nonrheumatoid joint effusions.

Authors:  C A Verburgh; M H Hart; L A Aarden; A J Swaak
Journal:  Clin Rheumatol       Date:  1993-12       Impact factor: 2.980

4.  Independent effects of interleukin 1 on proteoglycan synthesis and proteoglycan breakdown of bovine articular cartilage in vitro.

Authors:  J Neidel; U Zeidler
Journal:  Agents Actions       Date:  1993-05

Review 5.  Cytokines and autoimmunity.

Authors:  M G Cavallo; P Pozzilli; R Thorpe
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

6.  Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor alpha in the knee-joints of patients with rheumatoid arthritis.

Authors:  J Neidel; M Schulze; J Lindschau
Journal:  Inflamm Res       Date:  1995-05       Impact factor: 4.575

7.  Degradation of human cartilage by synovial fluid but not cytokines in vitro.

Authors:  A P Hollander; R M Atkins; D M Eastwood; P A Dieppe; C J Elson
Journal:  Ann Rheum Dis       Date:  1991-01       Impact factor: 19.103

Review 8.  Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response.

Authors:  Roger Gilabert-Oriol; Gemma M Ryan; Ada W Y Leung; Natalie S Firmino; Kevin L Bennewith; Marcel B Bally
Journal:  Int J Mol Sci       Date:  2018-09-26       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.